Biodesix Inc. (BDSX)
Biodesix Inc. (BDSX) Stock Price, Analysis & Data
| Bid | 16.49 |
| Market Cap | 245.31M |
| Revenue (ttm) | 102.94M |
| Net Income (ttm) | -27.76M |
| Beta | 0.56 |
| EPS (ttm) | -3.1 |
| PE Ratio (ttm) | n/a |
| Forward PE | -105.68 |
| P/B (ttm) | 26.82 |
| P/S (ttm) | 2.38 |
| Earnings Date | Nov 3, 2026 |
| Ask | 29.2 |
| Volume | 68,432 |
| Avg. Volume (20D) | 74,235 |
| Open | 23.88 |
| Previous Close | 24.00 |
| Day's Range | 22.96 - 25.27 |
| 52-Week Range | 5.26 - 25.52 |
| Analyst | Strong Buy |
| Price Target | 33.5 (44.09%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BDSX
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat...
Financial Performance
In 2025, Biodesix's revenue was 88.5M, an increase of 24.08% compared to the previous year's 71.32M. Earnings were -35.27M, a decrease of -17.86%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for BDSX stock is "Strong Buy". The 12-month stock price forecast is 33.5, which is upside of 44.09% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
